Get started
Ascendis Pharma A/S Sponsored ADRAscendis Pharma A/S Sponsored ADRAscendis Pharma A/S Sponsored ADR

Ascendis Pharma A/S Sponsored ADR

No trades
See on Supercharts
OverviewFinancialsNewsDocumentsDiscussionsTechnicalsForecastSeasonalsOptionsBondsETFs

ASND chart


Full chart

ASND upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪12.36 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−4.97 USD
Net income (FY)
‪−408.97 M‬ USD
Revenue (FY)
‪393.35 M‬ USD
Shares float
‪60.13 M‬
Beta (1Y)
0.56

About Ascendis Pharma A/S Sponsored ADR


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Jan Møller Mikkelsen
Website
ascendispharma.com
Headquarters
Hellerup
Founded
2006
ISIN
US04351P1012
FIGI
BBG007R7VNC1
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.

Check out other big names from the same industry as ASND.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ASND news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ASND highest yielding bonds


ASND5566766
Ascendis Pharma A/S 2.25% 01-APR-2028
Yield to maturity
—
Maturity date
Apr 1, 2028

See all ASND bonds 

ETFs with ASND exposure


IBB
iShares Biotechnology ETF
Weight
0.82%
Market value
‪50.76 M‬
USD
CGGR
Capital Group Growth ETF
Weight
0.20%
Market value
‪34.24 M‬
USD
TCAF
T. Rowe Price Capital Appreciation Equity ETF
Weight
0.17%
Market value
‪10.07 M‬
USD
XGSD
Xtrackers STOXX GLOBAL SELECT DIVIDEND 100 SWAP UCITS ETF Distribution 1D
Weight
1.06%
Market value
‪8.64 M‬
USD
FDG
American Century Focused Dynamic Growth ETF
Weight
2.50%
Market value
‪8.08 M‬
USD
SPDW
SPDR Portfolio Developed World ex-US ETF
Weight
0.02%
Market value
‪7.38 M‬
USD
AFOS
ARS Focused Opportunity Strategy ETF
Weight
3.86%
Market value
‪7.37 M‬
USD
MSSM
Morgan Stanley Pathway Small-Mid Cap Equity ETF
Weight
1.06%
Market value
‪7.32 M‬
USD
BTEC
iShares NASDAQ US Biotechnology UCITS ETF
Weight
1.10%
Market value
‪6.97 M‬
USD
BTEE
iShares NASDAQ US Biotechnology UCITS ETF
Weight
1.10%
Market value
‪6.97 M‬
USD
SBIO
Invesco NASDAQ Biotech UCITS ETF
Weight
1.10%
Market value
‪4.01 M‬
USD

Explore more ETFs